drugset / Trial / NCT02340325
FS2 Safety and Tolerability Study in Healthy Volunteers
Phase 1
Completed
20 enrolled
British Columbia Professional Firefighters' Burn and Wound Healing Laboratory
RandomizedSingle-groupTriple-blindTreatment
Summary
Background Scarring typically occurs after trauma, burn injury or surgery. Hypertrophic scarring presents as raised, red and itchy lesions which variably respond to various treatment modalities, such as corticosteroids, pressure garments, laser therapy, the use of silicone sheets and radiotherapy. Kynurenine, or "Fibrostop 1" (FS1), and its further breakdown products, such as kynurenic acid, or "Fibrostop 2" (FS2), are endogenous products found in many systems and have shown potential in reducing scar formation in animal studies. The aim of study is to evaluate the safety and tolerability of FS2 cream applied to the skin of healthy human subjects.
Timeline
- Start
- 2015-05
- Primary completion
- 2016-01
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | kynurenic acid | Unknown | 0.15 % | Topical |
| Subject | kynurenic acid | Unknown | 0.25 % | Topical |
| Subject | kynurenic acid | Unknown | 0.4 % | Topical |
| Subject | kynurenic acid | Unknown | 0.5 % | Topical |